Skip to main content
Caplight Logo









ExGen Dx

ExGen Dx

Private
BirminghamHealthcare & Life Scienceshttps://lineardiagnostics.com/

Last Round

Grant

Jun 9, 2025

Total Funding Raised

$1.75M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

ExGen Dx is a biotechnology company that develops rapid, point-of-care diagnostic tests for infectious diseases, particularly sexually transmitted infections, using its proprietary EXPAR and linear dichroism technologies.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Sensors

Business Model

B2B

Customer Profile

Usage-Based SaaS, Hardware Sales, Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

point-of-care diagnosticsrapid diagnosticsmolecular diagnosticsSTI testingPOC testinginfectious disease testingPOCTnucleic acid amplificationisothermal amplificationExponential Amplification ReactionEXPARLinear DichroismChlamydia and Gonorrhoea testantimicrobial resistanceAMRdisposable test cartridgelab-on-a-chip

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ExGen Dx Comparables

Compare ExGen Dx with similar companies based on industry and business-model similarity.

ExGen Dx comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Rapidemic
86%
binx health
81%
Visby Medical
78%

ExGen Dx Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 9, 2025
VC RoundFeb 24, 2021
VC RoundNov 14, 2019
SeedMay 24, 2017

ExGen Dx Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 12, 2026

    Monthly visitors increased 517% MoM, reaching 1.1K.

  • Jun 9, 2025

    $1.36M grant from the National Institute for Health and Care Research.

ExGen Dx Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ExGen Dx Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ExGen Dx's valuation, stock price, and market status.

Firmographic Details

HeadquartersBirmingham
Employee Range5
Year Founded2011
Last FundingJun 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?